Edition:
United States

Tetraphase Pharmaceuticals Inc (TTPH.OQ)

TTPH.OQ on NASDAQ Stock Exchange Global Select Market

2.85USD
17 Aug 2018
Change (% chg)

$-0.10 (-3.39%)
Prev Close
$2.95
Open
$2.94
Day's High
$2.94
Day's Low
$2.85
Volume
179,475
Avg. Vol
145,353
52-wk High
$7.98
52-wk Low
$2.06

Chart for

About

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral... (more)

Overall

Beta: 2.58
Market Cap(Mil.): $150.65
Shares Outstanding(Mil.): 52.86
Dividend: --
Yield (%): --

Financials

  TTPH.OQ Industry Sector
P/E (TTM): -- 28.29 30.45
EPS (TTM): -1.69 -- --
ROI: -77.63 12.92 12.63
ROE: -77.71 14.94 14.82

BRIEF-Tetraphase Pharma Q4 Loss Per Share $0.46

* TETRAPHASE PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS, HIGHLIGHTS ACHIEVEMENTS AND KEY 2018 MILESTONES

Mar 06 2018

BRIEF-Tetraphase Pharmaceuticals Says FDA Accepted NDA Filing For cIAI Treatment Eravacycline

* TETRAPHASE PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR FILING OF ITS NDA SUBMISSION FOR ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)

Feb 27 2018

BRIEF-Tetraphase Pharma Enters Exclusive Development And Commercialization Agreement With Everest Medicines

* TETRAPHASE PHARMACEUTICALS ENTERS INTO EXCLUSIVE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH EVEREST MEDICINES FOR ERAVACYCLINE IN CHINA

Feb 20 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $134.47 +1.99
Pfizer Inc. (PFE.N) $42.09 +0.67
Merck & Co., Inc. (MRK.N) $69.06 +0.21
AstraZeneca plc (AZN.L) 5,930.00 -6.00

Earnings vs. Estimates